EPOR and neoplasm: Tumor growth in the MDA-MB-231-D3H2-shEPOR subgroup treated with doxycycline (shSCR+dox) was dramatically reduced and showed substantially lower expression of EPOR by in situ hybridization than the control subgroups, indicating that EPO-EPOR axis is active in breast tumor progression in this model.